Literature DB >> 1384958

Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.

F Zhou1, B T Rouse, L Huang.   

Abstract

EG7-OVA cells are mouse thymoma EL4 cells stably transfected with the complementary DNA of chicken ovalbumin (OVA) and thus express OVA epitopes as a unique antigen. Cytotoxic T lymphocytes specific to OVA can be elicited by immunization of mice with OVA osmotically loaded into syngeneic splenocytes or entrapped in liposomes. Cytotoxic T lymphocytes thus induced can specifically cytolyse the EG7-OVA cells in vitro in an antigen-specific and major histocompatibility complex-restricted manner. In the present study, we have examined in this model system whether immunization with liposomal OVA can protect mice against tumors induced by EG7-OVA cells. Vaccination with OVA either entrapped in liposomes or osmotically loaded in the syngeneic splenocytes prolonged the survival of mice which had been challenged with EG7-OVA cells, but not those mice challenged with the parent EL4 cells. The antitumor effect was attributed to the induced OVA-specific cytotoxic T lymphocyte activity, since other forms of acquired immunity such as interaction of tumor cells with specific antibody could not be detected. Our results demonstrate that immunization with antigen incorporated in liposomes could be a useful means of inducing a protective antitumor response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384958

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

2.  Liposome targeting of high molecular weight DNA to the hair follicles of histocultured skin: a model for gene therapy of the hair growth processes.

Authors:  L Li; V Lishko; R M Hoffman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-04       Impact factor: 2.416

Review 3.  Enhancing the recognition of tumour associated antigens.

Authors:  N P Restifo; B R Minev; A S Taggarse; B J McFarland; M Wang; K R Irvine
Journal:  Folia Biol (Praha)       Date:  1994       Impact factor: 0.906

Review 4.  Prospects for the therapeutic use of anticancer vaccines.

Authors:  R S Chamberlain
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

5.  27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.

Authors:  Liqian Ma; Lawrence Wang; Adam T Nelson; Chaeyeon Han; Sisi He; Madeline A Henn; Karan Menon; Joy J Chen; Amy E Baek; Anna Vardanyan; Sayyed Hamed Shahoei; Sunghee Park; David J Shapiro; Som G Nanjappa; Erik R Nelson
Journal:  Cancer Lett       Date:  2020-08-28       Impact factor: 8.679

Review 6.  Gammadelta T cells play an essential role in several forms of tolerance.

Authors:  Judith A Kapp; Linda M Kapp; Kyle C McKenna
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.

Authors:  B R Minev; B J McFarland; P J Spiess; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

8.  Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.

Authors:  B J McCabe; K R Irvine; M I Nishimura; J C Yang; P J Spiess; E P Shulman; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

9.  Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.

Authors:  B Martinez-Kinader; G B Lipford; H Wagner; K Heeg
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

10.  Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.

Authors:  S M Geary; C D Lemke; D M Lubaroff; A K Salem
Journal:  Cancer Immunol Immunother       Date:  2011-05-28       Impact factor: 6.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.